Beovu vs. Eylea

Beovu (brolucizumab-dbll) Injection and Eylea (aflibercept) are human vascular endothelial growth factor (VEGF) inhibitors used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD).

Side effects of Beovu and Eylea that are similar include blurred vision, cataracts, bleeding in the eye, eye pain, and eye "floaters."

Side effects of Eylea that are different from Beovu include discomfort after the injection, watery eyes, swelling of the eyelids, vitreous detachment, increased pressure within the eye, and feeling as if something is in the eye.

Both Beovu and Eylea may interact with other drugs.

Common side effects of Beovu include:

• blurred vision,
• cataracts,
• bleeding in the eye,
• eye pain, and
• eye "floaters"

Common side effects of Eylea include:

• burst blood vessel in the eye,
• eye pain or discomfort after the injection,
• cataracts,
• watery eyes,
• blurred vision,
• swelling of the eyelids,
• vitreous detachment,
• eye "floaters,"
• increased pressure within the eye, and
• feeling as if something is in the eye.

Tell your doctor if you have serious side effects of Eylea including:

• eye pain or redness, swelling around your eyes;
• sudden vision problems;
• seeing flashes of light or "floaters" in your vision;
• eyes being more sensitive to light;
• sudden numbness or weakness, especially on one side of the body; or
• sudden severe headache, confusion, problems with speech or balance.

Beovu (brolucizumab-dbll) Injection is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).

Eylea (aflibercept) is a recombinate protein indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD). AMD is a common cause of blindness.

Beovu may interact with other drugs. Tell your doctor all medications and supplements you use.

Eylea may interact with other drugs. Tell your doctor all medications and supplements you use.

Beovu is administered by intravitreal injection. The recommended dose for Beovu is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.

Eylea is supplied as a preservative-free, sterile, aqueous solution in a single-use, glass vial designed to deliver 0.05 mL (50 microliters) of Eylea in the strength of 40 mg/ml. Eylea is injected into the eye either every four weeks or every eight weeks by an ophthalmologist. The recommended dose for Eylea is 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg(0.05 mL) via intravitreal injection once every 8 weeks (2 months). Eylea should not be used in those who have an active eye infection or active ocular inflammation.